Riskpilot← Back to searchSign inGet full accessNORDLYSLEGENE AS
ASActiveOrg 914141761Stortorget 4, 9008 TromsøGeneral medical practice activities · NACE 8621Est. 20143 employeesstor4.no
Revenue 2024
NOK 4,9M
+3% vs 2023
EBITDA margin
1.4%
-58% vs 2023
Equity ratio
31.3%
Financial strength
Net profit 2024
NOK -33K
-312% vs 2023
| Revenue | NOK 4,9M | +3% |
| EBITDA | NOK 68K | -58% |
| Net profit | NOK -33K | -312% |
| Total assets | NOK 946K | +6% |
| Equity | NOK 296K | -10% |
| Employees | 3 | — |
Legal name
NORDLYSLEGENE AS
Org number
914141761
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
10. september 2014
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Fire styremedlemmer i fellesskap.
Company purpose
Drift av fastlegekontor i tromsø kommune, for eiere som også vil være selvstendig næringsdrivende fastleger i samme kommune. Selskapet ansetter helsesekretærer, drifter lokaler og holder utstyr for allmennlegearbeid.
Address
Stortorget 4, 9008 Tromsø
Website
stor4.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 719 | 4 566 | 4 290 | 4 723 | 4 861 |
| Staff expenses | −1 442 | −1 683 | −1 769 | −1 940 | −2 035 |
| EBITDA | −24 | 243 | 46 | 163 | 68 |
| Depreciation & amort. | −23 | −60 | −108 | −103 | −83 |
| EBIT | −47 | 183 | −62 | 60 | −15 |
| Net financials | −4 | −9 | −16 | −18 | −18 |
| Profit before tax | −51 | 174 | −78 | 41 | −33 |
| Tax | −39 | 38 | −17 | 26 | −0 |
| Net profit | −12 | 136 | −61 | 16 | −33 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 520 | 946 | 828 | 893 | 946 |
| Equity | 239 | 375 | 314 | 330 | 296 |
| Long-term debt | 0 | 327 | 257 | 187 | 117 |
| Short-term debt | 281 | 244 | 257 | 376 | 533 |
| Total debt | 281 | 571 | 514 | 563 | 650 |
EBITDA margin
1.4%
This company
15.8%
Market median
-91% vs market
20202024
Equity ratio
31.3%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
-11.3%
This company
18.4%
Market median
-161% vs market
20202024
Net profit margin
-0.7%
This company
8.1%
Market median
-109% vs market
20202024
Asset turnover
5.14×
This company
1.12×
Market median
+359% vs market
20202024
Debt / equity
2.19×
This company
0.62×
Market median
-253% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2017 | |
| Board of Directors | 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 16.67% | 16.67% | 2023 | |
| Individual | 16.67% | 16.67% | 2023 | |
| Individual | 16.67% | 16.67% | 2024 | |
| Company | 16.67% | 16.67% | 2023 | |
| Individual | 16.67% | 16.67% | 2024 | |
| Individual | 16.67% | 16.67% | 2022 | |
| Individual | 16.67% | 16.67% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDLYSLEGENE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikal Samuel Tønsaas | Chairman | 0 companies |
| Andreas Sletten | Board of Directors | 0 companies |